Exxua (gepirone ER): what it is and who it’s for
Exxua is a once-daily, extended-release antidepressant approved in 2023 for adults with major depressive disorder (MDD). It belongs to a novel class selective 5-HT1A receptor agonists and is the first oral antidepressant that targets 5-HT1A receptors with high selectivity.
How Exxua works (in plain language)
- 5-HT1A partial agonism: enhances serotonin signaling in brain regions tied to mood, motivation, and anxiety, easing core depressive symptoms.
- Indirect 5-HT2A antagonism effects: helps balance circuits involved in cognition and emotional processing, supporting antidepressant and anxiolytic benefits.
Why clinicians are interested
- Receptor selectivity: highly selective for 5-HT1A (unlike buspirone), minimizing off-target effects.
- Lower rates of sexual dysfunction & weight gain: real-world experience and trial data suggest fewer dopaminergic disruptions than SSRIs/SNRIs, which often drive these side effects.
- Extended-release design: smoother 24-hour exposure and once-daily dosing may improve adherence.
Side effects and safety
Common (often dose-related)
- Dizziness, headache
- Nausea, dyspepsia, GI upset
- Drowsiness or fatigue; sleep disturbances
Less common
- Dry mouth, sweating, paresthesias
- Agitation or jitteriness
- Upper respiratory symptoms
Serious—seek care urgently
- Suicidal thoughts/behavior: boxed warning for younger adults, especially early in treatment or after dose changes.
- QT prolongation/arrhythmia risk: syncope, palpitations, collapse—higher risk with baseline prolonged QTc or interacting drugs.
- Mania/hypomania: in those with bipolar spectrum disorders.
- Serotonin syndrome: agitation, fever, tremor, clonus, diarrhea—risk increases with other serotonergic agents (e.g., MAOIs, linezolid, MDMA, St. John’s wort).
Who should not use Exxua (key contraindications)
- Known hypersensitivity to gepirone or excipients
- Severe hepatic impairment
- Baseline prolonged QTc or congenital long-QT syndrome
- Concurrent strong CYP3A4 inhibitors/inducers that meaningfully alter exposure
- Use of MAOIs currently or within the past 14 days (and required washouts)
Dosing basics (doctor-directed only)
Exxua ER tablets: 18.2 mg, 36.3 mg, 54.5 mg, 72.6 mg. Typical initiation is 18.2 mg once daily, titrated based on response and tolerability. Swallow whole (do not crush/chew/split). Consistency (same time daily) supports steady exposure.
Drug interactions to keep on the radar
- CYP3A4 modulators: potent inhibitors/inducers can alter gepirone levels; review all prescriptions, OTCs, and botanicals.
- Other QT-prolonging agents: additive risk; avoid combinations when possible.
- Serotonergic combinations: elevate serotonin syndrome risk—use caution and clear rationale.
- CNS depressants & alcohol: may amplify sedation/dizziness; avoid or limit.
Is Exxua addictive?
Exxua is not classified as a controlled substance, and azapirones like gepirone show low abuse potential. However, as with many antidepressants, physiological dependence can occur—so abrupt discontinuation may produce withdrawal-like (“discontinuation”) symptoms. Any dose changes should be medically guided with gradual tapering when appropriate.
Stopping safely (discontinuation)
If you and your prescriber decide to stop Exxua, a gradual taper helps minimize dizziness, nausea, sleep disruption, irritability, or sensory “zaps.” Slow down or pause the taper if symptoms surge; address sleep, anxiety, and GI effects with supportive, non-serotonergic strategies.
Choosing care that fits
- Outpatient psychiatry + therapy: first-line for most—medication management with CBT/DBT/MI for skills and relapse prevention.
- Higher-intensity programs (IOP/PHP): when symptoms, safety, or complexity require more structure without 24/7 admission.
- Inpatient/hospital care: for acute safety concerns, severe adverse effects, or complex medical/psychiatric needs.
Finding help on Long Island
Recovery is challenging and achievable. The right match between clinical needs, level of care, and personal preferences makes a real difference. Long Island Addiction Resources connects you with vetted programs across levels of care such as medical stabilization, residential treatment, partial hospitalization, intensive outpatient, standard outpatient, and recovery housing. We are a connector and guide, not a treatment facility, and we prioritize programs that provide person-centered, evidence-based care.
